Anticoagulant therapy at difficult-to-treat patients with atrial fibrillation
AbstractThe risk of stroke and systemic embolism in patients with atrial fibrillation increases with age and in patients with impaired renal function. Apixaban, a novel oral anticoagulant, was compared with warfarin in the ARISTOTLE trail and showed reduction of the rate of stroke, death and bleeding regardless of age and renal function.
Keywords:atrial fibrillation, stroke prevention, apixaban